BLIS Technologies Ltd BLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NZ$0.03
- Day Range
- NZ$0.03–0.03
- 52-Week Range
- NZ$0.01–0.03
- Bid/Ask
- NZ$0.03 / NZ$0.03
- Shares Outstanding
- 1.28B
- Market Cap
- NZ$31.98M
- Volume/Avg
- 20,829 / 538,903
Key Statistics
- Price/Earnings (Normalized)
- 46.04
- Price/Sales
- 2.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 47
- Website
- https://www.blis.co.nz
Valuation
Metric | BLT |
|---|---|
Price/Earnings (Normalized) | 46.04 |
Price/Book Value | 2.45 |
Price/Sales | 2.39 |
Price/Cash Flow | — |
Price/Earnings
BLT
Financial Strength
Metric | BLT |
|---|---|
Quick Ratio | 6.19 |
Current Ratio | 7.48 |
Interest Coverage | 21.32 |
Quick Ratio
BLT
Profitability
Metric | BLT |
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BLT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<mc@hwt | LOCK|^?V<% | $138B | |||
| Moderna Inc MRNA | LOCK|<%$D?&W | LOCK|T!B | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|>J%nBww | LOCK|lcPy | $93B | |||
| argenx SE ADR ARGX | LOCK|nm<%&#f | LOCK|<&h | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!>q^^H$ | LOCK|V@ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?THV>NH@ | LOCK|<w^#G | $30B | |||
| Incyte Corp INCY | LOCK|k?Hq<s% | LOCK|QR | $24B | |||
| BioNTech SE ADR BNTX | LOCK|q?vQ%d$ | LOCK|!#d | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|r@mrR^ | LOCK|!%xc | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|N#gj&B | LOCK|$b | $15B |
United States